Universal CAR T-cell

Universal CAR T-cell is an early-stage **hybrid CAR/PAR cell therapy** being developed by Tychon Biosciences for broad oncology applications. The program appears to use a universal or programmable **CAR-T cell therapy** architecture combined with the company's **protease-activated receptor T-cell** control strategy, with the goal of directing engineered T cells against cancer while incorporating protease-dependent activation features that may help tune activity within the tumor microenvironment. Public pipeline information lists no single disclosed molecular target for this asset and places it in the discovery to preclinical stage for broad oncology.

Other names

Universal CAR-THybrid CAR/PAR cell therapy